Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Inclusion criteria

• ✓. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
• ✓. documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening).
• ✓. must have a negative urine pregnancy test at Screening, and
• ✓. must use two forms of birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 30 days after final study drug administration. Acceptable forms include:
• ✓. Established use of oral, injected or implanted hormonal methods of contraception;
• ✓. Placement of an intrauterine device (IUD) or intrauterine system (IUS);
• ✓. Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
• ✓. Established use of oral, injected or implanted hormonal methods of contraception.